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Background: Niacin improves serum lipids, but has not consistently been shown to benefit patient outcomes, particularly in the statin era. The 
AIM-HIGH trial was stopped early due to lack of niacin efficacy. The HPS-2 THRIVE trial results are eagerly anticipated in March 2013. We sought to 
determine how niacin was prescribed in the US and Canada prior to these trials and related expenditures.
methods: We conducted a population-level cohort study using IMS Health National Prescription Audit™/IMS Brogan Compuscript® data from 
2002-09 to describe prescribing and expenditures of prescription niacin.
results: 696,000 niacin prescriptions were dispensed/month in the US in 12/2009. Per capita niacin prescriptions were ~6-fold higher in the US 
vs. Canada in 2009. In December 2009, 81.6% and 85.5% of all niacin prescriptions were for Niaspan®, the brand product, in the US and Canada. 
In 2009, Niaspan® expenditures in US dollars totaled $732,194,000 in the US and $12,377,867 in Canada. Per capita niacin expenditures, 
adjusted for differences in purchase price parity were nearly 7-fold higher in the US versus Canada.
conclusions: We found a marked difference in utilization and expenditures of niacin between the US and Canada, with a more conservative initial 
approach in Canada. Even in Canada, resources are increasingly being directed towards a drug that lacks strong evidence that it improves clinical 
outcomes in the statin era. Which approach is best may depend on the results that are expected from HPS-2 at this meeting.
 
